From: High serum C1q-binding adiponectin levels in male patients with acute coronary syndrome
All | NC group | SAP group | ACS group | |
---|---|---|---|---|
Number | 138 | 19 | 41 | 78 |
Age, years | 65 ± 1 (40–86) | 65 ± 2 (51–79) | 65 ± 1 (49–81) | 65 ± 1 (40–86) |
Body mass index, kg/m2 | 24.3 ± 0.3 (17.7-38.4) | 24.3 ± 1.0 (19.5-32.5) | 24.6 ± 0.6 (17.7-31.2) | 24.2 ± 0.4 (17.8-38.4) |
Visceral fat area, cm2 | 117 ± 5 (25–223) | 101 ± 13 (25–223) | 125 ± 10 (17–277) | 116 ± 6 (18–259) |
Subcutaneous fat area, cm2 | 130 ± 5 (22–361) | 124 ± 15 (45–329) | 142 ± 8 (50–224) | 126 ± 7 (22–361) |
Smoking (none-/ex-/current-smoker), n | 45/32/61 | 9/5/5 | 14/10/17* | 22/17/39 |
Diabetes mellitus, n | 69 (50%) | 10 (53%) | 29 (71%) | 30 (38%) |
sulfonyl ureas/glinides/biguanides/alpha glucosidase inhibitors/Insulin, n | 22/5/10/20/6 | 5/0/1/2/2 | 10/5/8/2/2 | 7/0/1/16/2 |
Hypertension, n | 92 (67%) | 15 (79%) | 27* (66%) | 50 (64%) |
calcium channel antagonists/angiotensin receptor blockers /β-blockers/diuretics, n | 44/70/62/9 | 7/2/2/0 | 21/20/4/4 | 16/48/56/5 |
Dyslipidemia, n | 61 (44%) | 7 (37%) | 24* (59%) | 30 (38%) |
Statins/fibrates/ezetimibe/cholestimide, n | 83/2/1/1 | 10/1/0/0 | 10/0/1/1 | 63/1/0/0 |
anti-platelet drugs (aspirin/ticlopidine/clopidogrel), n | 115/32/65 | 6/0/4 | 31/0/20 | 78/32/41 |
Family history of CAD, n | 13 (9%) | 2 (11%) | 3* (7%) | 8 (10%) |
Systolic blood pressure, mmHg | 138 ± 2 (90–217) | 139 ± 4 (108–173) | 138 ± 3 (100–175) | 138 ± 3 (90–217) |
Diastolic blood pressure, mmHg | 83 ± 1 (49–146) | 79 ± 2 (64–94) | 75 ± 2 (49–99) | 87 ± 2 (57–146)† |
Hemoglobin A1c (NGSP), % | 6.7 ± 0.1 (3.4-12.2) | 7.3 ± 0.4 (5.8-9.8) | 6.9 ± 0.2 (5.5-10.1) | 6.6 ± 0.2 (3.4-12.2) |
LDL-C, mg/dL | 112 ± 3 (20–250) | 114 ± 8 (58–154) | 107 ± 6 (49–197) | 115 ± 4 (20–250) |
Triglyceride, mg/dL | 122 ± 7 (24–611) | 124 ± 16 (49–263) | 140 ± 12 (59–374) | 113 ± 10 (24–611) |
HDL-C, mg/dL | 49 ± 1 (26–128) | 63 ± 4 (39–95) | 53 ± 3 (27–104) | 44 ± 2 (26–128)¶,† |
Creatinine, mg/dL | 0.85 ± 0.03 (0.47-1.34) | 0.86 ± 0.04 (0.60-1.20) | 0.85 ± 0.03 (0.60-1.30) | 0.91 ± 0.04 (0.47-1.34) |
Target lesions (LMCA/LAD/LCX/RCA), n | 2/64/20/33 | - | 2/20/14/5 | 0/44/6/28 |
Vessels (None/SVD/DVD/TVD), n | 19/72/32/15 | - | 0/22/14/5 | 0/50/18/10 |
Procedures (PCI/CABG), n | 118/1 | - | 40/1 | 78/0 |